Ensuring Access to the Full Range of WHO-Recommended Optimal Pediatric Antiretroviral Regimens:

Overview

Recent breakthroughs in the development and commercialization of effective, child-friendly antiretroviral (ARV) formulations mean that more children living with HIV (CLHIV) should have access to life-saving antiretroviral therapy (ART). However, ART coverage for infants and children still lags behind coverage for adults. Increased efforts are needed at global and national levels to support national HIV programs in achieving their goals of ensuring that HIV-exposed infants and children are diagnosed early, placed on optimal ART regimens and achieve viral load suppression. To do this, national HIV programs must quantify, procure, and supply the full range of optimal pediatric ARVs. This includes first-, second-, and third-line treatments, as well as alternative and backbone products needed to deliver WHO-recommended ART for children 0 to 15 years of age and as they grow and transition from one treatment regimen to another. Quantifying and planning for the full portfolio of effective, child-friendly pediatric ARV formulations will ensure that CLHIV adhere to their treatment, achieve viral suppression, and live healthy and productive lives. 

Briefs are available in English, French, Portuguese, and Swahili.